ReviewGlobal heart2022
Addressing Failures in Achieving Hypertension Control in Low- and Middle-Income Settings through Simplified Treatment Algorithms.
Review in Global heart, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effectiveness and Safety of Using Standardized Treatment Protocols for Hypertension Compared to Usual Care: A Meta-Analysis of Randomized Clinical Trials.Journal of clinical hypertension (Greenwich, Conn.) · 2025Pooled it
- Scaling integrated cardiovascular-kidney-metabolic care through primary health care in the Americas: a health policy analysis of HEARTS 2.0 implementation levers and architecture.Lancet regional health. Americas · 2026Review
- Evidence-informed prioritization of interventions for integrating hypertension management into cardiovascular-kidney-metabolic care in primary health care: HEARTS 2.0 Phase 3.American journal of hypertension · 2026Article
- Readiness to deliver integrated cardiovascular, kidney and metabolic care in primary healthcare: phase II of HEARTS 2.0 in 26 countries in the Americas.BMJ global health · 2026Article
- [HEARTS Pharmacy: A framework for integrating pharmacists in hypertension and cardiovascular disease risk management in primary careFarmácia HEARTS: um modelo para a integração de farmacêuticos na gestão dos riscos de hipertensão arterial e doenças cardiovasculares na atenção primária].Revista panamericana de salud publica = Pan American journal of public health · 2026Article
- Translating Guidelines, Protocols, and Care Pathways for Hypertension Into Effective Program Implementation.American journal of hypertension · 2026Article
- Longitudinal trends in stroke risk factors and mortality over 20 years from a central stroke referral center in Pakistan using clinically digitized data.eNeurologicalSci · 2025Article
- Stroke Outcomes in a Population-Focused Urban Hypertension Program in Brazil and Senegal.Journal of the American Heart Association · 2025Article
- Cardiovascular disease in the Americas: optimizing primary and secondary prevention of cardiovascular disease series: cardiovascular disease in the Americas.Lancet regional health. Americas · 2025Review
- HEARTS Pharmacy: A framework for integrating pharmacists in hypertension and cardiovascular disease risk management in primary care.Revista panamericana de salud publica = Pan American journal of public health · 2025Article
- Evaluating the World Health Organization's Hearts Model for Hypertension and Diabetes Management: A Pilot Implementation Study in Guatemala.Global heart · 2025Article
- Acceptability of fixed-dose combination treatments for hypertension in Kenya: A qualitative study using the Theoretical Framework of Acceptability.PLOS global public health · 2025Article
- HEARTS in the Americas: Targeting Health System Change to Improve Population Hypertension Control.Current hypertension reports · 2024Review
- Barriers to access to antihypertensive medicines: insights from the HEARTS initiative in latin American and Caribbean region.Journal of pharmaceutical policy and practice · 2024Article
- [HEARTS in the Americas: targeting health system change to improve population hypertension controlHEARTS nas Américas: impulsionar mudanças no sistema de saúde para melhorar o controle da hipertensão arterial na população].Revista panamericana de salud publica = Pan American journal of public health · 2024Article
- Real-World Prescribing Patterns for Hypertensive Children in China from 2018 to 2021: A Cross-Sectional Multicenter Study.Risk management and healthcare policy · 2023Article
- Most Recent Trials and Advances in Hypertension.European cardiology · 2022Review
- [HEARTS in the Americas: innovations for improving hypertension and cardiovascular disease risk management in primary careHEARTS nas Américas: inovações para melhorar a gestão do risco de hipertensão e de doenças cardiovasculares na atenção primária].Revista panamericana de salud publica = Pan American journal of public health · 2022Article
- HEARTS in the Americas: innovations for improving hypertension and cardiovascular disease risk management in primary care.Revista panamericana de salud publica = Pan American journal of public health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Hypertension is the most important risk factor for cardiovascular diseases (CVDs), which are the leading global cause of death. Hypertension is under-diagnosed and under-treated in most low- and middle-income countries (LMICs). Current algorithms for hypertension treatment are complex for the healthcare worker, limit decentralization, complicate procurement and often translate to a large pill burden for the person with hypertension. We summarize evidence supporting implementation of simple, algorithmic, accessible, non-toxic and effective (SAANE) algorithms to provide a feasible way to access and maintain quality care for hypertension. Implementation of these algorithms will enable task shifting to less specialised health care workers and lay cadres, provision of fixed dose combinations, consolidation of the market while retaining generic competition, simplification of laboratory requirements, and lowering costs for health systems and people who incur out of pocket expenses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.